Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data

References

• Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–499.
   PubMed Web of Science ®Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Prostate Cancer 2020; [cited 2020 October 19]. Available from: https://seer.cancer.gov/statfacts/html/prost.html.
   Google Scholar
• Cattrini C, Castro E, Lozano R, et al. Current treatment options for metastatic hormone-sensitive prostate cancer. Cancers. 2019;11(9):1355.
   PubMed Web of Science ®Google Scholar
• Helgstrand JT, Roder MA, Klemann N, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer. 2018;124(14):2931–2938.
   PubMed Web of Science ®Google Scholar
• Rajaram P, Rivera A, Muthima K, et al. Second-generation androgen receptor antagonists as hormonal therapeutics for three forms of prostate cancer. Molecules. 2020;25(10):2448.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182–191.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Potluri RC, Ng Y, et al. Disease and treatment characteristics of men diagnosed with metastatic hormone-sensitive prostate cancer in real life: analysis from a commercial claims database. Clin Genitourin Cancer. 2017;15(2):273–279 e1.
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Gravel J, Grittner A, et al. Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases. Am Health Drug Benefits. 2013;6(6):307–316.
   PubMedGoogle Scholar
• Wen L, Valderrama A, Costantino ME, et al. Real-world treatment patterns in patients with castrate-resistant prostate cancer and bone metastases. Am Health Drug Benefits. 2019;12(3):142–149.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. 2018; [cited 2020 July 29]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive#:∼:text=On%20February%207%2C%202018%2C%20the,sensitive%20prostate%20cancer%20(CSPC).
   Google Scholar
• Food and Drug Administration (FDA). FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. 2019; [cited 2020 July 31]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer.
   Google Scholar
• National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer. 2020. p. 1–167. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved; [cited November 5, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Wu T, Zhao J, Liu Z, et al. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer? Prostate. 2019;79(14):1673–1682.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Bui C, Fitch K, et al. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Curr Med Res Opin. 2017;33(6):1133–1139.
   PubMed Web of Science ®Google Scholar
• Behl AS, Ellis LA, Pilon D, et al. Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide. Am Health Drug Benefits. 2017;10(6):296–303.
   PubMed Web of Science ®Google Scholar
• Caram MEV, Estes JP, Griggs JJ, et al. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer. 2018;18(1):258.
   PubMed Web of Science ®Google Scholar
• Caram MEV, Ross R, Lin P, et al. Factors associated with use of Sipuleucel-T to treat patients with advanced prostate cancer. JAMA Netw Open. 2019;2(4):e192589.
   PubMed Web of Science ®Google Scholar
• Caram MEV, Wang S, Tsao P, et al. Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer. Urol Pract. 2019;6(4):234–242.
   PubMed Web of Science ®Google Scholar
• Dharmani C, Bonafede M, Krivoshik A. Risk factors for and incidence of seizures in metastatic castration-resistant prostate cancer: a real-world retrospective cohort study. Clin Drug Investig. 2017;37(12):1183–1190.
   PubMed Web of Science ®Google Scholar
• Ellis LA, Lafeuille MH, Gozalo L, et al. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. Am Health Drug Benefits. 2015;8(4):185–195.
   PubMed Web of Science ®Google Scholar
• Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ. 2012;15(5):836–843.
   PubMedGoogle Scholar
• Pilon D, Behl AS, Ellis LA, et al. Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide. J Manag Care Spec Pharm. 2017;23(2):225–235.
   PubMed Web of Science ®Google Scholar
• Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naïve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018;35(10):1639–1655.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Huang A, Wang L, et al. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. BJU Int. 2018;121(6):871–879.
   PubMed Web of Science ®Google Scholar
• Wen L, Yao J, Valderrama A. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manag Care Spec Pharm. 2019;25(3-b Suppl):S1–S11.
   PubMed Web of Science ®Google Scholar
• Malangone-Monaco E, Foley K, Varker H, et al. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: results of an oncology EMR analysis. Clin Ther. 2016;38(8):1817–1824.
   PubMed Web of Science ®Google Scholar
• Oh WK, Cheng WY, Miao R, et al. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol. 2018;36(11):500 e1–500 e9.
   PubMed Web of Science ®Google Scholar
• Oh WK, Miao R, Vekeman F, et al. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol. 2017;34(9):160.
   PubMed Web of Science ®Google Scholar
• Unger JM, Hershman DL, Martin D, et al. The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst. 2015;107(2):dju412.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer. 2019. p. 1–151. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved; [cited November 5, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Optum. Clinformatics™ Data Mart. 2014. p. 1–4.
   Google Scholar
• Centers for Medicare & Medicaid Services. Standard Analytical Files (Medicare Claims) - LDS 2019; [cited 2020 September 14]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/StandardAnalyticalFiles.
   Google Scholar
• National Cancer Institute (NCI). NCI Dictionaries: Visceral 2020; [cited 2020 November 5]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/visceral.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar